Seaport Therapeutics Reports Q1 Loss and IPO Success
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 08 2026
0mins
Source: seekingalpha
- Financial Performance: Seaport Therapeutics reported a GAAP EPS of -$10.34 for Q1 2026, indicating ongoing investment in R&D and operations despite financial pressures.
- Cash Reserves: As of March 31, 2026, the company had $212.6 million in cash, cash equivalents, and investments, which is expected to support its operating plans into 2029, ensuring stability for the coming years.
- IPO Success: Following March 31, 2026, Seaport completed its IPO, raising gross proceeds of $260 million, providing crucial funding for further development, although underwriting discounts and other expenses will be deducted.
- Net Loss Comparison: The net loss for Q1 2026 was $25.4 million, compared to a net loss of $13.1 million in Q1 2025, highlighting challenges in financial management and cost control that may affect investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SPTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SPTX
Wall Street analysts forecast SPTX stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 17.100
Low
Averages
High
Current: 17.100
Low
Averages
High
About SPTX
Seaport Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Its product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder. It is also advancing Glyph2BLS (SPT-348 or Glyph 2-bromo-LSD), a novel, Glyphed oral prodrug of the non-hallucinogenic LSD analog 2-bromo-LSD, in preclinical studies for depressive disorders. GlyphAllo is designed to overcome the bioavailability limitations of allopregnanolone and be durable in MDD.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Seaport Therapeutics Reports Wider Net Loss in Q1 2026
- Wider Financial Loss: Seaport Therapeutics reported a net loss of $25.41 million for Q1 2026, translating to $10.34 per share, which is a significant increase from last year's loss of $13.13 million or $5.65 per share, indicating ongoing pressures in the market alongside substantial R&D investments.
- Increased R&D Expenses: The R&D expenses for Q1 2026 reached $21.43 million, up from $10.5 million in the same quarter last year, primarily driven by the advancement of GlyphAllo and GlyphAgo into later stages of development, showcasing the company's commitment to innovation in therapeutics.
- Strong Cash Position: As of March 31, 2026, Seaport had $212.6 million in cash, cash equivalents, and investments, which is expected to sustain operations through 2029, reflecting robust financial management and strategic planning.
- Upcoming Milestones: The company anticipates releasing data from the Phase 1 simulation trial of GlyphAllo in the second half of 2026 and expects to present topline data from the BUOY-1 Phase 2b trial for Major Depressive Disorder in the first half of 2027, indicating a proactive approach to clinical development and market readiness.
See More
Seaport Therapeutics Reports Positive Clinical Data for GlyphAgo
- Clinical Trial Success: Seaport Therapeutics successfully demonstrated favorable safety and tolerability in the multiple-ascending dose (MAD) portion of its Phase 1 trial for GlyphAgo, supporting further development in patients with generalized anxiety disorder (GAD).
- Dose Selection Support: Seven-day dosing of GlyphAgo achieved therapeutic exposure levels projected to avoid liver enzyme elevations, thereby reducing or eliminating the need for liver function testing, which will aid in dose selection for future clinical trials.
- Future Trial Plans: Seaport plans to initiate a Phase 2a trial in the second half of 2026 to assess GlyphAgo's potential benefits on sleep in anxiety patients, with topline data expected in early 2028, and a Phase 2b trial is set for the first half of 2027.
- Platform Advantages: The development of GlyphAgo leverages PureTech's Glyph platform, showcasing its innovative ability to overcome drug metabolism limitations, and is expected to provide new treatment options for GAD patients, addressing a 20-year gap in new drug approvals in this area.
See More
Seaport Therapeutics Reports Q1 Loss and IPO Success
- Financial Performance: Seaport Therapeutics reported a GAAP EPS of -$10.34 for Q1 2026, indicating ongoing investment in R&D and operations despite financial pressures.
- Cash Reserves: As of March 31, 2026, the company had $212.6 million in cash, cash equivalents, and investments, which is expected to support its operating plans into 2029, ensuring stability for the coming years.
- IPO Success: Following March 31, 2026, Seaport completed its IPO, raising gross proceeds of $260 million, providing crucial funding for further development, although underwriting discounts and other expenses will be deducted.
- Net Loss Comparison: The net loss for Q1 2026 was $25.4 million, compared to a net loss of $13.1 million in Q1 2025, highlighting challenges in financial management and cost control that may affect investor confidence.
See More
Seaport Therapeutics Raises $260 Million in Successful IPO
- Successful IPO Financing: Seaport Therapeutics completed an upsized IPO in May 2026, raising $260 million in gross proceeds, which will support the company's operations into 2029, reflecting strong market confidence in its neuropsychiatric drug development.
- Clinical Trial Progress: New data from the Phase 1 trial of GlyphAgoTM indicate that a seven-day dosing regimen can achieve therapeutic exposures at doses projected to avoid liver enzyme elevations, potentially reducing or eliminating the need for liver function testing, thereby enhancing patient safety.
- New Board Member Appointment: Dr. Sharon Mates has been appointed to Seaport's Board of Directors; she previously served as the Co-Founder and CEO of Intra-Cellular Therapies, bringing extensive industry experience that is expected to drive the company's strategic development in the neuropsychiatry field.
- Increased R&D Spending: Research and development expenses for Q1 2026 were $21.4 million, significantly up from $10.5 million in Q1 2025, primarily due to accelerated clinical development of GlyphAlloTM and GlyphAgoTM, reflecting the company's ongoing commitment to new drug development.
See More
GlyphAgo Repeat Dosing Shows Favorable Safety Profile
- Clinical Trial Results: GlyphAgo demonstrated a favorable safety and tolerability profile in the multiple ascending dose trial with healthy volunteers, with no liver-related adverse events observed, laying a solid foundation for its further development in generalized anxiety disorder patients.
- Pharmacokinetic Advantages: The seven-day dosing regimen achieved therapeutic exposures of agomelatine that are projected to avoid liver enzyme elevations, thereby reducing or eliminating the need for liver function testing, significantly enhancing clinical applicability.
- Future Trial Plans: Seaport plans to initiate two parallel Phase 2 clinical trials in the second half of 2026, aimed at validating the efficacy and safety of GlyphAgo for patients with generalized anxiety disorder, potentially providing new treatment options for patients.
- Enhanced Bioavailability: In crossover trials, GlyphAgo showed a 6.8-fold increase in bioavailability compared to unmodified agomelatine, with 10-fold lower pharmacokinetic variability across different doses, further demonstrating its potential in clinical applications.
See More
Latest Wall Street Rating Updates
- Vipshop Rating Upgrade: UBS upgraded Vipshop (VIPS) from Neutral to Buy, indicating that despite near-term growth pressures, the company's earnings quality and shareholder returns are more attractive, showcasing resilience in a competitive e-commerce landscape.
- Seaport Therapeutics Initiation: JPMorgan initiated coverage on Seaport Therapeutics (SPTX) with an Overweight rating and a price target of $42 for December 2027, reflecting bullish sentiment and highlighting the company's potential for growth in the biotech sector.
- Apple Price Target Increase: Bank of America raised its price target on Apple (AAPL) from $330 to $380, emphasizing significant opportunities in agentic AI, while reiterating a Buy rating, which underscores confidence in the company's future growth trajectory.
- Dave Inc. Initial Rating: UBS initiated coverage on Dave Inc. with a Buy rating and a price target of $300, suggesting that the market underestimates the durability of its high-velocity credit model and earnings growth trajectory, indicating strong future potential.
See More
Seaport Therapeutics Reports Wider Net Loss in Q1 2026
- Wider Financial Loss: Seaport Therapeutics reported a net loss of $25.41 million for Q1 2026, translating to $10.34 per share, which is a significant increase from last year's loss of $13.13 million or $5.65 per share, indicating ongoing pressures in the market alongside substantial R&D investments.
- Increased R&D Expenses: The R&D expenses for Q1 2026 reached $21.43 million, up from $10.5 million in the same quarter last year, primarily driven by the advancement of GlyphAllo and GlyphAgo into later stages of development, showcasing the company's commitment to innovation in therapeutics.
- Strong Cash Position: As of March 31, 2026, Seaport had $212.6 million in cash, cash equivalents, and investments, which is expected to sustain operations through 2029, reflecting robust financial management and strategic planning.
- Upcoming Milestones: The company anticipates releasing data from the Phase 1 simulation trial of GlyphAllo in the second half of 2026 and expects to present topline data from the BUOY-1 Phase 2b trial for Major Depressive Disorder in the first half of 2027, indicating a proactive approach to clinical development and market readiness.
See More
Seaport Therapeutics Reports Positive Clinical Data for GlyphAgo
- Clinical Trial Success: Seaport Therapeutics successfully demonstrated favorable safety and tolerability in the multiple-ascending dose (MAD) portion of its Phase 1 trial for GlyphAgo, supporting further development in patients with generalized anxiety disorder (GAD).
- Dose Selection Support: Seven-day dosing of GlyphAgo achieved therapeutic exposure levels projected to avoid liver enzyme elevations, thereby reducing or eliminating the need for liver function testing, which will aid in dose selection for future clinical trials.
- Future Trial Plans: Seaport plans to initiate a Phase 2a trial in the second half of 2026 to assess GlyphAgo's potential benefits on sleep in anxiety patients, with topline data expected in early 2028, and a Phase 2b trial is set for the first half of 2027.
- Platform Advantages: The development of GlyphAgo leverages PureTech's Glyph platform, showcasing its innovative ability to overcome drug metabolism limitations, and is expected to provide new treatment options for GAD patients, addressing a 20-year gap in new drug approvals in this area.
See More
Seaport Therapeutics Reports Q1 Loss and IPO Success
- Financial Performance: Seaport Therapeutics reported a GAAP EPS of -$10.34 for Q1 2026, indicating ongoing investment in R&D and operations despite financial pressures.
- Cash Reserves: As of March 31, 2026, the company had $212.6 million in cash, cash equivalents, and investments, which is expected to support its operating plans into 2029, ensuring stability for the coming years.
- IPO Success: Following March 31, 2026, Seaport completed its IPO, raising gross proceeds of $260 million, providing crucial funding for further development, although underwriting discounts and other expenses will be deducted.
- Net Loss Comparison: The net loss for Q1 2026 was $25.4 million, compared to a net loss of $13.1 million in Q1 2025, highlighting challenges in financial management and cost control that may affect investor confidence.
See More
Seaport Therapeutics Raises $260 Million in Successful IPO
- Successful IPO Financing: Seaport Therapeutics completed an upsized IPO in May 2026, raising $260 million in gross proceeds, which will support the company's operations into 2029, reflecting strong market confidence in its neuropsychiatric drug development.
- Clinical Trial Progress: New data from the Phase 1 trial of GlyphAgoTM indicate that a seven-day dosing regimen can achieve therapeutic exposures at doses projected to avoid liver enzyme elevations, potentially reducing or eliminating the need for liver function testing, thereby enhancing patient safety.
- New Board Member Appointment: Dr. Sharon Mates has been appointed to Seaport's Board of Directors; she previously served as the Co-Founder and CEO of Intra-Cellular Therapies, bringing extensive industry experience that is expected to drive the company's strategic development in the neuropsychiatry field.
- Increased R&D Spending: Research and development expenses for Q1 2026 were $21.4 million, significantly up from $10.5 million in Q1 2025, primarily due to accelerated clinical development of GlyphAlloTM and GlyphAgoTM, reflecting the company's ongoing commitment to new drug development.
See More
GlyphAgo Repeat Dosing Shows Favorable Safety Profile
- Clinical Trial Results: GlyphAgo demonstrated a favorable safety and tolerability profile in the multiple ascending dose trial with healthy volunteers, with no liver-related adverse events observed, laying a solid foundation for its further development in generalized anxiety disorder patients.
- Pharmacokinetic Advantages: The seven-day dosing regimen achieved therapeutic exposures of agomelatine that are projected to avoid liver enzyme elevations, thereby reducing or eliminating the need for liver function testing, significantly enhancing clinical applicability.
- Future Trial Plans: Seaport plans to initiate two parallel Phase 2 clinical trials in the second half of 2026, aimed at validating the efficacy and safety of GlyphAgo for patients with generalized anxiety disorder, potentially providing new treatment options for patients.
- Enhanced Bioavailability: In crossover trials, GlyphAgo showed a 6.8-fold increase in bioavailability compared to unmodified agomelatine, with 10-fold lower pharmacokinetic variability across different doses, further demonstrating its potential in clinical applications.
See More
Latest Wall Street Rating Updates
- Vipshop Rating Upgrade: UBS upgraded Vipshop (VIPS) from Neutral to Buy, indicating that despite near-term growth pressures, the company's earnings quality and shareholder returns are more attractive, showcasing resilience in a competitive e-commerce landscape.
- Seaport Therapeutics Initiation: JPMorgan initiated coverage on Seaport Therapeutics (SPTX) with an Overweight rating and a price target of $42 for December 2027, reflecting bullish sentiment and highlighting the company's potential for growth in the biotech sector.
- Apple Price Target Increase: Bank of America raised its price target on Apple (AAPL) from $330 to $380, emphasizing significant opportunities in agentic AI, while reiterating a Buy rating, which underscores confidence in the company's future growth trajectory.
- Dave Inc. Initial Rating: UBS initiated coverage on Dave Inc. with a Buy rating and a price target of $300, suggesting that the market underestimates the durability of its high-velocity credit model and earnings growth trajectory, indicating strong future potential.
See More
